AYAConnect
Phase NA Completed
63 enrolled
HERO
Phase NA Completed
113 enrolled
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Phase 1 Completed
117 enrolled
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Phase 1/2 Completed
49 enrolled
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
Phase NA Completed
434 enrolled
GASVERT
Phase 3 Completed
744 enrolled
A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy
Phase NA Completed
74 enrolled 8 charts
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
Phase 1 Completed
53 enrolled
ONCODAGE
Phase NA Completed
1,674 enrolled 9 charts
Effects of High-intensity Training Compared to Resistance Training in Cancer Patients Undergoing Radiotherapy
Phase NA Completed
78 enrolled
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Phase 1/2 Completed
25 enrolled 14 charts
EPAC
Phase NA Completed
213 enrolled 20 charts
Spectroscopy With Surface Coils and Decoupling
Phase 1 Completed
582 enrolled
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
Phase 1 Completed
43 enrolled
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
14 enrolled
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
Phase 1/2 Completed
66 enrolled
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
Phase 3 Completed
130 enrolled 9 charts
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Phase 1 Completed
41 enrolled
Chemotherapy in Treating Patients With Solid Tumors
Phase 1/2 Completed
57 enrolled
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
Phase 2 Completed
180 enrolled
Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer
Completed
25 enrolled
Immunoreactivity to Cetuximab in Cancer Patients
Completed
538 enrolled
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Phase 1 Completed
15 enrolled
Biological Therapy in Treating Patients With Metastatic Cancer
Phase 1 Completed
24 enrolled
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
24 enrolled
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
48 enrolled
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase 1 Completed
75 enrolled
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
75 enrolled
Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases
Phase 1 Completed
27 enrolled
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Phase 1 Completed
26 enrolled